Company intelligence / Profile preview

Cell Biopeutics

Not stated, Wilayah Persekutuan, Malaysiacellbiopeutics.com ↗

Ownership: Private
Development stage: Commercial

Overview

Cell Biopeutics developed the first allogeneic cell therapy product approved for commercial use in India and globally for Critical Limb Ischemia. Their pooled MSC product demonstrates strong immune-modulatory properties, consistent clinical outcomes, and is also being explored for anti-aging and regenerative applications. The company collaborates internationally with governments, clinicians, and researchers to advance stem cell therapies.

Therapeutic areas: OtherRare DiseasesCardiovascular
Modalities: Allogeneic mesenchymal stem cells (MSCs)Stem cell-derived cosmetic products
Industry: Biotech

Drug pipeline

1 asset

Stempeucel

Commercial

Indications: Critical limb ischemia

Partnerships

Collaborates with governments, clinicians, and researchers worldwide on stem cell treatments

Beyond the preview

Go deeper on Cell Biopeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cell Biopeutics.

Explore the full profile